Tegoprubart to be Used as Immunosuppressive Agent in Cohort C of Sernova’s Phase 1/2 Cell Pouch Bio-hybrid Organ Clinical Trial in Patients with Type 1 Diabetes ...

WALTHAM, MA, USA I July 9, 2025 I Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for ...

BASEL, Switzerland / MUNICH, Germany I July 10, 2025 I NUCLIDIUM, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

SHANGHAI, China I July 9, 2025 I Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma"), a clinical-stage biopharmaceutical company dedicated to innovative ...

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of ...

PRAGUE, Czech Republic I July 9, 2025 I Zentiva Group and global pharmaceutical company Lupin Limited, have entered into a license and supply agreement for ...

OSLO, Norway and CAMBRIDGE, MA, USA I July 9, 2025 I Actithera, a radiopharmaceutical biotech company translating medicinal chemistry insights into ...

CHICAGO, IL, USA I July 09, 2025 I MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted ...

MARTINSRIED, Germany, and MARSEILLE, France I July 10, 2025 I Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of ...

SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

Zodasiran targets ANGPLT3, an emerging therapeutic target to treat HoFH and other dyslipidemias – YOSEMITE Phase 3 study further enhances Arrowhead’s late-stage pipeline o ...

SAN DIEGO, CA, USA I July 08, 2025 I Eluciderm, Inc., a clinical-stage pharmaceutical company developing small molecule therapeutics designed to promote ...